AIHTA - Publications - Search - Everolimus (Afinitor®) for advanced/metastatic kidney cancer

Nachtnebel, A. (2009): Everolimus (Afinitor®) for advanced/metastatic kidney cancer. DSD: Horizon Scanning in Oncology 03.

[thumbnail of DSD_HSO_Nr.03.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the treatment of advanced or metastasised renal cell carcinoma (RCC). A placebo controlled phase III study showed improved progression free survival and acceptable side-effects for the intervention group.
Nevertheless, with the availability of a number of new drugs for the treatment of RCC, the remaining challenge is the determination of the best sequence or combination of these therapies.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Kidney cancer, renal cell cancer, everolimus, afinitor, oncology
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WJ Urogenital system > WJ 300-378 Kidney
Series Name:DSD: Horizon Scanning in Oncology 03
Deposited on:19 Oct 2009 08:05
Last Modified:15 Jul 2020 17:42

Repository Staff Only: item control page